Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data

Hernández-Vásquez AML(2017)Psoriasis in Latin America and the Caribbean: a systematic review J Eur Acad Dermatol Venereol. 31 1991-1998

Larrea N(2020)Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials J Dermatolog Treat. 33 1-9

Ciapponi A(2015)Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis N Engl J Med 373 2534-2548

Gottlieb AB(2014)Secukinumab in plaque psoriasis–results of two phase 3 trials N Engl J Med 371 326-338

Wu JJ(2015)Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet 386 1137-1146

Griffiths CEM(2015)Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial J Am Acad Dermatol. 73 400-409

Baeten D(2017)Secukinumab is efficacious and safe in Hispanic patients with moderate-to-severe plaque psoriasis: pooled analysis of four phase 3 trials Adv Ther. 34 1327-1339

Sieper J(2017)Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study Br J Dermatol 177 1033-1042

Braun J(2020)US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry J Dermatolog Treat 31 333-341

Langley RG(2020)Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) Br J Dermatol 183 294-302

Hernández-Vásquez AML(2017)Psoriasis in Latin America and the Caribbean: a systematic review J Eur Acad Dermatol Venereol. 31 1991-1998

Larrea N(2020)Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials J Dermatolog Treat. 33 1-9

Ciapponi A(2015)Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis N Engl J Med 373 2534-2548

Gottlieb AB(2014)Secukinumab in plaque psoriasis–results of two phase 3 trials N Engl J Med 371 326-338

Wu JJ(2015)Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet 386 1137-1146

Griffiths CEM(2015)Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial J Am Acad Dermatol. 73 400-409

Baeten D(2017)Secukinumab is efficacious and safe in Hispanic patients with moderate-to-severe plaque psoriasis: pooled analysis of four phase 3 trials Adv Ther. 34 1327-1339

Sieper J(2017)Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study Br J Dermatol 177 1033-1042

Braun J(2020)US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry J Dermatolog Treat 31 333-341

Langley RG(2020)Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) Br J Dermatol 183 294-302